Drug Approval | November 03, 2022
Glenmark receives ANDA approval for Sodium Phenylbutyrate Tablets
Glenmark’s Sodium Phenylbutyrate Tablets USP, 500 mg, will be distributed in the U.S. by Glenmark Pharmaceuticals USA.
Glenmark’s Sodium Phenylbutyrate Tablets USP, 500 mg, will be distributed in the U.S. by Glenmark Pharmaceuticals USA.
According to IQVIA sales data for the 12-month period ending September 2022, the Gilenya Capsules, 0.5 mg market achieved annual sales of approximately US $1.8 billion
The expansion program includes investments in France and the U.S., adding an additional 23,000+ m² of manufacturing footprint.
Gland Pharma Q2 FY2023 consolidated net profit up at Rs. 241.24 Cr
Pluvicto and Scemblix launches are progressing well and we are awaiting data in earlier lines of therapy.
He is a seasoned business leader with a successful track record of over 26 years across local and area roles within the pharmaceutical industry
Yoshindo gets exclusive commercialization rights in Japan for bUstekinumab and bDenosumab developed and manufactured by Biocon Biologics
Acquisition brings leading sickle cell disease portfolio and pipeline to Pfizer with potential to address critical needs in an underserved patient community
The reduction in force will result in financial savings of approximately $50 million annually beginning in 2023
The two overhead tanks commissioned at a cost of Rs 57 lakh will be maintained by the village panchayats.
Subscribe To Our Newsletter & Stay Updated
